ArticleFrontiers in oncology2025
Association of the triglyceride-glucose index with immunotherapy efficacy and long-term prognosis in advanced Non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC), the most common subtype of primary lung cancer, represents a major component of the global cancer burden. Despite the availability of several immunotherapeutic and immune-combination treatment modalities, its prognosis remains poor. Therefore, it is particularly important to predict the prognosis of these patients. Aim: To investigate whether a marker of insulin resistance [the triglyceride-glucose (TyG) index] could predict clinical outcomes in patients with advanced non-small cell lung cancer receiving pembrolizumab and chemotherapy. Methods: We retrospectively analyzed data of 243 patients with advanced non-small cell lung cancer treated with pembrolizumab and chemotherapy, dividing them into high and low TyG index groups based on an optimal cut-off value of 1.61, determined using the X-tile software. Cox proportional hazards regression analysis identified independent prognostic factors for overall survival (OS), and a prediction nomogram model was developed based on them. Results: The study cohort included 132 patients with a high TyG index and 111 with a low TyG index. The median progression-free survival and OS in the low TyG index group were significantly longer than in the high TyG index group. The objective response rate was 45.05% in the low TyG index group and 25.76% in the high TyG index group, while the respective disease control rates were 85.59% and 53.03%. Multifactorial regression analysis identified pre-treatment maximum tumor diameter, PD-L1 TPS (Tumor Proportion Score), BMI(Body Mass Index), and TyG index as independent prognostic predictors of OS. The nomogram model emphasized the importance of the TYG index as a major prognostic predictor, followed by the PD-L1 TPS score, pre-treatment tumor diameter, and BMI. Conclusion: The TyG index is a long-term predictor of the efficacy of combined immunotherapy and chemotherapy in patients with advanced NSCLC. Patients with a low TyG index have a better prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.